UCB and Biogen's lupus drug falls short at Phase 2b

The anti-CD40L pegylated fab was tested in 182 patients with the condition who had not seen results despite receiving standard-of-care treatments like corticosteroids, non-biological immunosuppressants and non-malarials, in groups randomised to receive it in combination with these treatments at one of three doses. However, it failed to demonstrate a dose response after 24 weeks, according to the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA).

Despite this, the pair did note that top-line results demonstrated that the therapy produced "consistent and potentially meaningful improvements for the majority of clinical endpoints" compared with placebo, and that biomarker data showed evidence of proof of biology.

"Biogen and UCB continue to further evaluate these data while assessing potential next steps. The companies expect to present this data at a future scientific forum," the pair concluded.

-----------------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.